$0.67
Orgenesis is a biotechnology business based in the US. Orgenesis shares (ORGS) are listed on the NASDAQ and all prices are listed in US Dollars. Orgenesis employs 146 staff and has a trailing 12-month revenue of around $662,000.
Our top picks for where to buy Orgenesis stock
How to buy Orgenesis stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ORGS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Orgenesis stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Orgenesis stock price (NASDAQ: ORGS)
Use our graph to track the performance of ORGS stocks over time.Orgenesis shares at a glance
Latest market close | $0.67 |
---|---|
52-week range | $0.25 - $1.08 |
50-day moving average | $0.71 |
200-day moving average | $0.56 |
Wall St. target price | $6.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.80 |
Is it a good time to buy Orgenesis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Orgenesis price performance over time
Historical closes compared with the close of $0.6698 from 2024-09-04
1 week (2024-08-29) | -2.62% |
---|---|
1 month (2024-08-05) | -9.83% |
3 months (2024-06-05) | 33.96% |
6 months (2024-03-05) | -18.49% |
1 year (2023-09-05) | -10.69% |
---|---|
2 years (2022-09-02) | -64.93% |
3 years (2021-09-03) | 5.1 |
5 years (2019-09-05) | 4.24 |
Orgenesis financials
Revenue TTM | $662,000 |
---|---|
Gross profit TTM | $36 million |
Return on assets TTM | -30.08% |
Return on equity TTM | -727.25% |
Profit margin | 0% |
Book value | $-0.33 |
Market Capitalization | $31.4 million |
TTM: trailing 12 months
Orgenesis share dividends
We're not expecting Orgenesis to pay a dividend over the next 12 months.
Have Orgenesis's shares ever split?
Orgenesis's shares were split on a 1:12 basis on 15 November 2017. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Orgenesis shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Orgenesis shares which in turn could have impacted Orgenesis's share price.
Orgenesis share price volatility
Over the last 12 months, Orgenesis's shares have ranged in value from as little as $0.25 up to $1.0799. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orgenesis's is 1.223. This would suggest that Orgenesis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Orgenesis overview
Orgenesis Inc. , a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc.
Frequently asked questions
What percentage of Orgenesis is owned by insiders or institutions?Currently 21.519% of Orgenesis shares are held by insiders and 4.664% by institutions. How many people work for Orgenesis?
Latest data suggests 146 work at Orgenesis. When does the fiscal year end for Orgenesis?
Orgenesis's fiscal year ends in December. Where is Orgenesis based?
Orgenesis's address is: 20271 Goldenrod Lane, Germantown, MD, United States, 20876 What is Orgenesis's ISIN number?
Orgenesis's international securities identification number is: US68619K2042 What is Orgenesis's CUSIP number?
Orgenesis's Committee on Uniform Securities Identification Procedures number is: 68619K105
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question